September 25/Seattle/Marketwired -- Plandaí Biotechnology Inc., a producer of highly bioavailable plant extracts, announced it has executed a letter of intent with a major producer of nutraceutical cold and flu remedies under which all of 2014 estimated production capacity of Phytofare Limonoid Glycoside Complex, estimated at 15 tons, will be purchased. The letter of intent is subject to favorable results from a clinical trial which is expected to commence late in 2013.

Plandaí's Phytofare Limonoid Glycoside Complex is derived from lemons, utilizing the entire fruit -- pith, peel, pulp and juice -- and is rich in the entire spectrum of 170 phytochemicals including flavonoids, vitamin C, and limonoid glycosides (antioxidants). Prior clinical investigations of citrus bioflavonoids showed improved wellness benefits in combating allergic and vasomotor rhinitis (common cold). This includes the lowering of chills, feverishness, headache or general aching, nasal stiffness or discharge, sore throat, cough and sputum expectoration.

Roger Duffield, chairman and chief executive officer of Plandaí Biotechnology, commented, "Over a hundred clinical publications on citrus bioflavonoids demonstrates conclusive evidence of flavonoid efficacy in addressing capillary permeability, alleviating symptoms of the common cold and providing inflammatory relief. We are confident that the higher purity and increased bioavailability of our Phytofare Limonoid Glycoside Complex will yield improved results over the earlier studies which lacked the superior bioactive properties of Phytofare."